skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis

Oncotarget, 2017-05, Vol.8 (19), p.31347-31354

Copyright: © 2017 Zhang et al. 2017 ;ISSN: 1949-2553 ;EISSN: 1949-2553 ;DOI: 10.18632/oncotarget.15532 ;PMID: 28430626

Full text available

Citations Cited by
  • Title:
    Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
  • Author: Zhang, Minghui ; Sun, Houbin ; Zhao, Shu ; Wang, Yan ; Pu, Haihong ; Wang, Yan ; Zhang, Qingyuan
  • Subjects: B7-H1 Antigen - genetics ; Biomarkers, Tumor ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Neoplasm Metastasis ; Neoplasm Staging ; Odds Ratio ; Prognosis ; Proportional Hazards Models ; Publication Bias ; Research Paper ; Tumor Burden
  • Is Part Of: Oncotarget, 2017-05, Vol.8 (19), p.31347-31354
  • Description: The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of various cancers have always been a research topic of considerable interest. However, the prognostic value of PD-L1 in breast cancer patients remains a controversial subject. We aimed to assess the association between PD-L1 protein expression and clinicopathological features and the impact of this relationship on breast cancer survival. We performed a systematic search of the PubMed, EMBASE, and Cochrane Library databases to determine the correlations among PD-L1 expression, clinicopathological features and overall survival (OS). A total of 5 studies containing 2,546 cases were included in the analysis. The combined hazard ratio (HR) and its 95% confidence interval (CI) for OS were 1.76 (95% CI 1.09-2.82; P=0.02) for patients with tumors exhibiting PD-L1 overexpression. The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC). Our findings indicate that PD-L1 expression is a promising biomarker for the prognosis of breast cancer, and may be helpful to clinicians aiming to select the appropriate immunotherapy for breast cancer.
  • Publisher: United States: Impact Journals LLC
  • Language: English
  • Identifier: ISSN: 1949-2553
    EISSN: 1949-2553
    DOI: 10.18632/oncotarget.15532
    PMID: 28430626
  • Source: GFMER Free Medical Journals
    MEDLINE
    PubMed Central
    Alma/SFX Local Collection
Back to results list
Go to Previous pagePrevious Result  3 NextGo to Next page
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait